Frequently Asked Questions

Important Information for Patients, Prescribers, and Pharmacy Teams

The NSPMP tracks the utilization of monitored drugs in the province and provides reporting and support services that promote good prescribing practices and inform research activities. 

The collection of prescription data will inform prescribers and other program stakeholders about prescribing practices and use of the drugs in Nova Scotia. These learnings can help to reduce associated risks such as interactions with other medications, over-sedation, and potential injury or overdose.

The NSPMP currently monitors various drugs also listed under the Controlled Drugs and Substances Act (Canada), such as opioids and stimulants, and is adding benzodiazepines as part of its 2017-2020 Strategic Plan activities. 

The NSPMP’s Strategic Plan also prioritizes support for the goals and objectives of the Nova Scotia Opioid Use and Overdose Framework. NSPMP will work with partners and stakeholder groups to support the First Prescription Initiative and tailor monitoring approaches to focus on initial prescriptions of opioids and help prevent overprescribing for acute pain.  

We have prepared this downloadable “Frequently Asked Questions” document to help explain important aspects of our Program and outline the elements of our 2017 – 2020 Strategic Plan.

Still have questions? Let us know. We’re here to help. Email the NSPMP Team: pmp@medavie.bluecross.ca